# Pluri Inc.: overview PLUR · Nasdaq · CIK 1158780 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/plur.md) · [Financials](/companies/plur/financials.md) · [Filings](/companies/plur/filings.md) · [Insiders](/companies/plur/insiders.md) Latest reported revenue: [$335.0k](/filings/0001213900-26-098862.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 10, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-098862). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [326](/filings/0001213900-25-109174.md) | [185](/filings/0001213900-26-015550.md) | [427](/filings/0001213900-26-056586.md) | [398 d](/filings/0001213900-26-098862.md) | [316](/filings/0001213900-25-109174.md) | [198](/filings/0001213900-26-015550.md) | [167](/filings/0001213900-26-056586.md) | [335 d](/filings/0001213900-26-098862.md) | | Gross margin | % | [61.3%](/filings/0001213900-25-109174.md) | [60.0%](/filings/0001213900-26-015550.md) | [31.9%](/filings/0001213900-26-056586.md) | [52.0% d](/filings/0001213900-26-098862.md) | [36.4%](/filings/0001213900-25-109174.md) | [43.4%](/filings/0001213900-26-015550.md) | [33.5%](/filings/0001213900-26-056586.md) | [58.5% d](/filings/0001213900-26-098862.md) | | Operating margin | % | [(1594.5%)](/filings/0001213900-25-109174.md) | [(2679.5%)](/filings/0001213900-26-015550.md) | [(1264.6%)](/filings/0001213900-26-056586.md) | [(1663.6%) d](/filings/0001213900-26-098862.md) | [(2009.5%)](/filings/0001213900-25-109174.md) | [(3285.9%)](/filings/0001213900-26-015550.md) | [(3913.8%)](/filings/0001213900-26-056586.md) | [(1655.5%) d](/filings/0001213900-26-098862.md) | | Net margin | % | [(1804.3%)](/filings/0001213900-25-109174.md) | [(1597.8%)](/filings/0001213900-26-015550.md) | [(1439.6%)](/filings/0001213900-26-056586.md) | [(1909.0%) d](/filings/0001213900-26-098862.md) | [(1851.3%)](/filings/0001213900-25-109174.md) | [(3304.5%)](/filings/0001213900-26-015550.md) | [(3322.2%)](/filings/0001213900-26-056586.md) | [(1755.2%) d](/filings/0001213900-26-098862.md) | | Diluted EPS | $ per share | [(1.08)](/filings/0001213900-25-109174.md) | [(0.53)](/filings/0001213900-26-015550.md) | [(0.94)](/filings/0001213900-26-056586.md) | not reported | [(0.65)](/filings/0001213900-25-109174.md) | [(0.71)](/filings/0001213900-26-015550.md) | [(0.55)](/filings/0001213900-26-056586.md) | not reported | | Free cash flow | $k | [(4,272)](/filings/0001213900-25-109174.md) | [(4,740) d](/filings/0001213900-26-015550.md) | [(4,880) d](/filings/0001213900-26-056586.md) | [(5,937) d](/filings/0001213900-26-098862.md) | [(5,544)](/filings/0001213900-25-109174.md) | [(5,652) d](/filings/0001213900-26-015550.md) | [(4,556) d](/filings/0001213900-26-056586.md) | [(4,469) d](/filings/0001213900-26-098862.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001213900-23-076079.md) | [0.3](/filings/0001213900-24-079861.md) | [0.3](/filings/0001213900-25-088578.md) | [1.3](/filings/0001213900-26-098862.md) | [1.0](/filings/0001213900-26-098862.md) | | Gross margin | % | [100.0%](/filings/0001213900-23-076079.md) | [96.9%](/filings/0001213900-24-079861.md) | [98.8%](/filings/0001213900-25-088578.md) | [49.0%](/filings/0001213900-26-098862.md) | [44.6%](/filings/0001213900-26-098862.md) | | Operating margin | % | [(17774.8%)](/filings/0001213900-23-076079.md) | [(9493.4%)](/filings/0001213900-24-079861.md) | [(6796.9%)](/filings/0001213900-25-088578.md) | [(1659.9%)](/filings/0001213900-26-098862.md) | [(2454.5%)](/filings/0001213900-26-098862.md) | | Net margin | % | [(17624.8%)](/filings/0001213900-23-076079.md) | [(9867.9%)](/filings/0001213900-24-079861.md) | [(6407.4%)](/filings/0001213900-25-088578.md) | [(1690.3%)](/filings/0001213900-26-098862.md) | [(2344.6%)](/filings/0001213900-26-098862.md) | | Diluted EPS | $ per share | [(1.28)](/filings/0001213900-23-076079.md) | [(6.24)](/filings/0001213900-24-079861.md) | [(3.99)](/filings/0001213900-25-088578.md) | [(3.56)](/filings/0001213900-26-098862.md) | [(2.44)](/filings/0001213900-26-098862.md) | | Free cash flow | $m | [(36.8)](/filings/0001213900-23-076079.md) | [(23.1)](/filings/0001213900-24-079861.md) | [(18.3)](/filings/0001213900-25-088578.md) | [(19.8)](/filings/0001213900-26-098862.md) | [(20.2)](/filings/0001213900-26-098862.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/plur/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-23 | [Manieu Alexandre Weinstein](/insiders/1833124.md) | Director, 10% owner | Purchase (P) | 833,334 | $1.50 | $1.3m | [Form 4](/filings/0001213900-26-112641.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $38.3k | 18,324 | | Reduced −1,100 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $6.2k | 2,982 | | Reduced −94 | | [EverSource Wealth Advisors, LLC](/funds/1710537.md) | 2026-06-30 | $4.2k | 2,000 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $4.0k | 1,918 | | Added +1,823 | | [SIMA Wealth Partners, LLC](/funds/2135539.md) | 2026-06-30 | $732 | 350 | | Unchanged | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $393 | 191 | | Reduced −1,169 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $386 | 185 | | Unchanged | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $269 | 125 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $203 | 97 | | Unchanged | | [TD Waterhouse Canada Inc.](/funds/1999606.md) | 2026-06-30 | $198 | 95 | | Added +2 | ## Recent filings [All 731 filings](/companies/plur/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 06:07 ET | [SCHEDULE 13D/A](/filings/0001213900-26-112643.md) | Ownership report, active investor, amended | 0001213900-26-112643 | | 2026-10-20 | 16:00 ET | [8-K](/filings/0001213900-26-111015.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-111015 | | 2026-10-06 | 16:00 ET | [S-1](/filings/0001213900-26-107182.md) | Registration statement | 0001213900-26-107182 | | 2026-09-10 | 17:19 ET | [10-K](/filings/0001213900-26-098862.md) | Annual report, period 2026-06-30 | 0001213900-26-098862 | | 2026-08-28 | 07:33 ET | [8-K](/filings/0001213900-26-094638.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-094638 | | 2026-08-17 | 16:01 ET | [8-K](/filings/0001213900-26-090738.md) | 8.01 Other events | 0001213900-26-090738 | | 2026-07-14 | 16:01 ET | [8-K](/filings/0001213900-26-077960.md) | 8.01 Other events | 0001213900-26-077960 | | 2026-07-13 | 16:05 ET | [8-K](/filings/0001213900-26-077548.md) | 3.01 Delisting notice | 0001213900-26-077548 | | 2026-07-01 | 16:01 ET | [SCHEDULE 13D/A](/filings/0001213900-26-074213.md) | Ownership report, active investor, amended | 0001213900-26-074213 | | 2026-06-22 | 16:01 ET | [8-K](/filings/0001213900-26-070609.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-070609 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001213900-26-098862.md), filed Sep 10, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b8e292eb-1d24-472f-9375-f487df993316) ## About the filer - CIK: 1158780 - Tickers: PLUR - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 08:31 ET. No prices; not investment advice.